Tricyclic pyrazoles. Part 5. novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 ligands using molecular hybridization based on scaffold hopping

Open Medicinal Chemistry Journal

Volumn 6, Issue 1, 2012, Pages 1-14

  Murineddu, Gabriele ^a   Asproni, Battistina ^a   Ruiu, Stefania ^b   Deligia, Francesco ^a   Falzoi, Matteo ^b   Pau, Amedeo ^a   Thomas, Brian F ^c   Zhang, Yanan ^c   Pinna, Gérard A ^a   Pani, Luca ^b,e   Lazzari, Paolo ^a,d  

^a UNIVERSITY OF SASSARI   (Italy)

^b INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^c RTI INTERNATIONAL   (United States)

^d Neuroscienze PharmaNess Scarl   (Italy)

^e Italian Drug Agency(AIFA)   (Italy)

Author keywords

Cannabinoid 2 receptors; Hybridization; In vitro assay; Scaffold hopping; Structure activity relationships; Tricyclic pyrazoles

Indexed keywords

1 (2,4 DICHLOROPHENYL) 6 METHYL N (PIPERIDIN 1 YL) 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N FENCHYL 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 2 RECEPTOR AGONIST; N (1 CYCLOHEXYL) 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N (1 CYCLOHEXYLETHYL) 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N (4 METHYLCYCLOHEXYL) 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N (HOMOPIPERIDIN 1 YL) 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N (NAPHTHALEN 1 YL) 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N (PYRROLIDIN 1 YL) 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N 1 ADAMANTANMETHYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N [1 (1 NAPHTHYL)ETHYL] 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N ADAMANT 1 YL 6 CHLORO 1 (2,4 DICHLOROPHENYL) 7 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N ADAMANT 1 YL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N ADAMANT 2 YL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N BORNYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N CYCLOHEPTYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N FENCHYL 6 CHLORO 1 (2,4 DICHLOROPHENYL) 7 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N FENCHYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N ISOPINOCAMPHEYL 6 CHLORO 1 (2,4 DICHLOROPHENYL) 7 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N ISOPINOCAMPHEYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N MENTHYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; N MYRTANYL 7 CHLORO 1 (2,4 DICHLOROPHENYL) 6 METHYL 1,4 DIHYDROINDENO [1,2 C]PYRAZOLE 3 CARBOXAMIDE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR HYBRIDIZATION; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

EID: 84861913403     PISSN: None     EISSN: 18741045     Source Type: Journal    
DOI: 10.2174/1874104501206010001     Document Type: Article

References (52)

1. Dewane, W. A.; Hanús, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949.
2. Mechoulam, R.; Ben-Shabat, S.; Hanús, L.; Ligumsky, M.; Kamin-ski, N. E.; Shatz, A. R.; Gobher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, T.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50, 83-90.
3. Sugiura, T.; Kondo, S.; Sukawaga, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamasita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid ligand in the brain. Biochem. Biophys. Res. Commun., 1995, 215, 89-97.
4. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C. Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564.
5. Munro, S; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65.
6. Boyd, S. T. The endocannabinoid system. Pharmacotherapy, 2006, 26, 218S-221S.
7. Piomelli, D. The endocannabinoid system: A drug discovery perspective. Curr. Opin. Investig. Drugs, 2005, 6, 672-679.
8. Fried, E.; Foox, A.; Rosemberg, E.; Faigenboim, M.; Cohen, V.; Barda, L.; Blau, H.; Mechoulam, R. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: Evidence for a CB3 receptor. Eur. J. Pharmacol., 2003, 461, 27-34.
9. Lange, J. H. M.; Kruse, C. G. Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov. Today, 2005, 10, 693-702.
10. Glass, M. The role of cannabinoids in neurodegenerative disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 2001, 25, 743-765.
11. Pertwee, R. G. Canabinoids and gastrointestinal tract. Gut, 2001, 48, 859-867.
12. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K., Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54, 161-202.
13. Bouaboula, M.; Dussossoy, D.; Casellas, P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J. Biol. Chem., 1999, 274, 20397-20405.
14. Pertwee, R. G. The pharmacology of cannabinoid receptors and their ligands: An overview. Int. J. Obes., 2006, 30 (Suppl 1), S13-S18.
15. R. G. Cannabinoid pharmacology: The first 66 years. Br. J. Pharmacol., 2006, 147 (Suppl 1), S163-S171.
16. Jbilo, O.; Derocq, J. M.; Segue, M.; Le Fur, G.; Casellas, P. Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. FEBS Lett., 1999, 448, 273-277.
17. Kishimoto, S.; Kobayashi, Y.; Oka, S.; Gokoh, M.; Waku, K.; Sugiura, T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem., 2004, 135, 517-524.
18. Sugiura, T.; Oka, S.; Gokoh, M.; Kishimoto, S.; Waku, K. New perspectives in the studies on endocannabinoid and cannabis: 2-Arachidonoylglycerol as a possible novel mediator of inflammation. J. Pharmacol. Sci., 2004, 96, 367-375.
19. Carrier, E. J.; Kearn, C. S.; Barkmeier, A. J.; Breese, N. M.; Yang, W.; Nithipatikom, K.; Pfister, S. L.; Campbell, W. B.; Hillard, C. J. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonoylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol. Pharmacol., 2004, 65, 999-1007.
20. Do, Y.; McKallip, R. J.; Nagarkatti, M.; Nagarkatti, P. S. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: Novel role for endogenous and exogenous cannabinoids in immunoregulation. J. Immunol., 2004, 173, 2373-2382.
21. Onaivi, E. S.; Ishiguro, H.; Gong, J. P.; Patel, S.; Perchuk, A.; Meozzi, P. A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; Brusco, A.; Akinshola, B. E.; Liu, Q. R.; Hope, B.; Iwasaki, S.; Arinani, T.; Teasenfitz, L.; Uhl, G. R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N.Y. Acad. Sci., 2006, 1074, 514-536.
22. Flygar, J.; Gustafsson, K.; Kimby, E.; Christensson, B.; Sander, B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett., 2005, 578, 6885-6889.
23. Herrera, B.; Carracedo, A.; Diez-Zaera, M.; Guzman, M; Velasco, G. p38 Mapk is involved in CB2 receptor-induced apoptosis of human leukemia cells. FEBS Lett., 2005, 579, 5084-5088.
24. Pryce, G.; Baker, D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci., 2005, 28, 272-276.
25. Benito, C.; Romero, J. P.; Tólon, R. M.; Clement, D.; Docagne, F.; Hillard, C. J.; Guaza, C.; Romero, J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J. Neurosci., 2007, 27, 2396-2402.
26. Baker, D.; Pryce, G.; Croxford, J. L.; Brown, P.; Pertwee, R. G.; Huffman, J. W.; Layward, L. Cannabinoids control spasticity and tumor in a multiple sclerosis model. Nature, 2000, 404, 84-87.
27. Benito, C.; Núñez, E.; Tólon, R. M.; Carrier, E. J.; Rábano, A.; Hillard, C. J.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plasma-associated glia in Alzheimer's disease brains. J. Neurosci., 2003, 23, 11136-11141.
28. Hanús, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fried, E. HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA, 1999, 96, 14228-14233.
29. Malan, T. P. Jr; Ibrahim, M. M.; Lai, J.; Vanderah, T. W.; Makri-yannis, A.; Porreca, F. CB2 cannabinoid receptors agonists: pain relief without psychoactive effects? Curr. Opin. Pharmacol., 2003, 3, 62-67.
30. Clayton, N.; Marshall, F. M.; Bountra, C.; O'Shaughnessy, C. T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 2002, 96, 253-260.
31. Quartino, A.; Mata, H. P.; Ibrahim, M. M.; Vanderah, T. W.; Por-reca, F.; Makriyannis, A.; Malan, T. P. Jr. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology, 2003, 99, 955-960.
32. Bermudez-Silva, F. J.; Sanches-Vera, I.; Suárez, J.; Serrano, A.; Fuentes, E.; Juan-Pico, P.; Nadal, A.; de Fonseca, F. R. Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur. J. Pharmacol., 2007, 565, 207-211.
33. Page, D.; Yang, H.; Brown, W.; Walpole, C.; Fleurent, M.; Fyfe, M.; Gaudreault, F.; St-Onge, S. New 1,2,3,4-tetrahydropyrrolo[3,4-b]indole derivatives as selective CB2 receptor agonists. Bioorg. Med. Chem. Lett., 2007, 17, 6183-6187.
34. Giblin, G. M. P.; O'Shaughnessey, C. T.; Naylor, A.; Mitchell, W. L.; Eatherton, A. J.; Slingsby, B. P.; Rawlings, D. A.; Goldsmith, P.; Brown, A. J.; Haslam, C. P.; Clayton, N. M.; Wilson, A. W.; Chessel, I. P.; Wittington, A. R.; Green, R. Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of inflammatory pain. J. Med. Chem., 2007, 50, 2597-2600.
35. Huffmann, J. W. CB2 receptor ligands. Mini Rev. Med. Chem., 2005, 5, 641-649.
36. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulket, J. M.; Gootshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Else-more, D. A.; Toth, M.; Koetzner, L.; Whoiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology, 2005, 48, 658-672.
37. Huffman, J. W.; Yu, S.; Showalter, V.; Abood, M. E.; Wiley, J. L.; Compton, D. R.; Martin, B. R.; Bramblett, R. D.; Reggio, P. H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem., 1996, 39, 3875-3877.
38. Mussinu, J-M.; Ruiu, S.; Mulè, A. C.; Pau, A.; Carai, M. A. M.; Loriga, G.; Murineddu, G.; Pinna, G. A. Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg. Med. Chem., 2003, 11, 251-263.
39. Manera, C.; Benetti, V.; Castelli, M. P.; Cavallini, T.; Lazzarotti, S.; Pibiri, F.; Saccomanni, G.; Tuccinardi, T.; Vannacci, A.; Marti-nelli, A.; Ferrarini, P. L. Design, synthesis and biological evaluation of new 1,8-Naphthyridin-4(1H)-on-3-carboxamide and quino-lin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. J. Med. Chem., 2006, 49, 5947-5957.
40. Salo, O. M.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lathela-Kakkonen, M.; Laitinen, J. T.; Jarvinen, T.; Poso, A. A virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem., 2005, 48, 7166-7171.
41. Ohta, H.; Ishizaka, T.; Yoshinaga, M.; Morita, A.; Tomishima, Y.; Toda, Y.; Saito, S. Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists. Bioorg. Med. Chem. Lett., 2007, 17, 5133-5135.
42. Ohta, H.; Ishizaka, T.; Tatsuzuki, M.; Yoshinaga, M.; Iida, I.; Tomishima, Y.; Toda, Y.; Saito, S. N-Alkylidenearylcarboxamides as new potent and selective CB2 cannabinoid receptor agonists with good oral bioavailability. Bioorg. Med. Chem. Lett., 2007, 17, 6299-6304.
43. Yao, B. B.; Hsieh, G. C.; Frost, T. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Khandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br. J. Pharmacol., 2008, 153, 390-401.
44. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J-M.; Casellas, P.; Congy, C.; Oustric, D.; Saran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Brelière, J-C.; Lefur, G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 1998, 284, 644-650.
45. Murineddu, G.; Lazzari, P.; Ruiu, S.; Sanna, A.; Loriga, G.; Manca, I.; Falzoi, M.; Dessì, C.; Curzu, M. M.; Chelucci, G.; Pani, L.; Pinna, G. A. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabi-noid ligand 1-(2,4-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazolo-3-carboxamide. J. Med. Chem., 2006, 49, 7502-7512.
46. Poso, A.; Huffman, J. W. Targeting the cannabinoid CB2 receptor: modeling and structural determinants of CB2 selective ligands. Br. J. Pharmacol., 2008, 153, 335-346.
47. 1 J. Am. Chem. Soc., 1950, 72, 3286-3287.
48. Luongo, L.; Palazzo, E.; Tambaro, S.; Giordano, C.; Gatta, L.; Scafuro, M.A.; Rossi, F.sca; Lazzari, P.; Pani, L.; de Novellis, V.; Malcangio, M.; Maione, S. 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxami-de,- a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol. Dis., 2010, 37, 177-185;
49. Guindon, J.; Hohmann, A.G.; Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br. J. Pharmacol., 2008, 153, 319-334.
50. Suchocki, J. A.; May, E. L.; Martin, T. J.; George, C., Martin, B. R., Synthesis of 2-exo- and 2-endo-mecamylamine analogs. Structure-activity relationships for nicotinic antagonism in the central nervous system. J. Med. Chem., 1991, 34, 1003-1010.
51. M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 1976, 72, 248-254.
52. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 1973, 22, 3099-3108.